FDA Expands Label for AZN’s Cancer Drug Calquence ... 498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Disc Medicine, Inc. will hold a conference call on January 21, 2025, at 8:00 am EST to discuss feedback from the FDA regarding its investigational drug, bitopertin, for treating Erythropoietic ...
Amgen AMGN announced that the FDA has approved its KRAS inhibitor ... 498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity ...
The company expects to regain compliance with Nasdaq Listing Rule 5250(c)(1), which ... by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
The FDA has approved MediBeacon®'s TGFR system for noninvasive kidney function assessment, targeting both normal and impaired renal patients. INNOVATE Corp. announced the FDA approval of the ...
(RTTNews) - Amgen, Inc. (AMGN) a biopharmaceutical company on Friday, announced that the FDA has approved LUMAKRAS or sotorasib in combination with Vectibix or panitumumab for the treatment of ...
Eli Lilly and Company LLY announced that the FDA has granted approval to its drug ... list of today’s Zacks #1 Rank (Strong Buy) stocks here. It's only 1/9,000th the size of NVIDIA which ...
(RTTNews) - AstraZeneca (AZN), on Friday, announced that the FDA has approved CALQUENCE in ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Currently, Amgen's stock is trading at $272.83, up 1.26 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback